Home › Research › TREM2 and immune genetics
Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease
Schlepckow K, Morenas-Rodríguez E, Hong S, Haass C.. The Lancet. Neurology, 2023-11-01
Topic: Brain proteins, microglia and lab models
Neurodegenerative disorders, including Alzheimer's disease, are associated with microgliosis. Microglia have long been considered to have detrimental roles in Alzheimer's disease. However, functional analyses of genes encoding risk factors that are linked to late-onset Alzheimer's disease, and that are enriched or exclusively expressed in microglia, have revealed unexpected protective functions.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schlepckow, K., Morenas-Rodríguez, E., Hong, S., & Haass, C. (2023). Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(23)00247-8
Vancouver
Schlepckow K, Morenas-Rodríguez E, Hong S, Haass C. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease. The Lancet. Neurology. 2023. doi:10.1016/s1474-4422(23)00247-8. PMID: 37863592.
BibTeX
@article{schlepckow2023-37863592,
author = {Schlepckow, K. and Morenas-Rodríguez, E. and Hong, S. and Haass, C.},
title = {{Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease}},
journal = {The Lancet. Neurology},
year = {2023},
doi = {10.1016/s1474-4422(23)00247-8},
pmid = {37863592},
url = {https://doi.org/10.1016/s1474-4422(23)00247-8}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Microglia have long been considered to have detrimental roles in Alzheimer's disease.
- However, functional analyses of genes encoding risk factors that are linked to late-onset Alzheimer's disease, and that are enriched or exclusively expressed in microglia, have revealed unexpected protective functions.
- One of the major risk genes for Alzheimer's disease is TREM2.
- Risk variants of TREM2 are loss-of-function mutations affecting chemotaxis, phagocytosis, lipid and energy metabolism, and survival and proliferation.
Why it matters
This review discusses the idea that stimulating TREM2 with agonistic antibodies could be a therapeutic option, based on evidence that some microglial genes have protective functions. It is a review of a proposed approach, not a tested treatment, and reports no cure or prevention.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 54/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet. Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 113 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 22.6 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 4 / 6 | Cited 9.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 113 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Christian Haass: h-index 139 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37863592) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 69.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.